SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED

Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.

Metadata

Authors/Creators:
  • Ritchlin, CT
  • Helliwell, P
  • Boehncke, WH
  • Hsia, EC
  • Kollmeier, A
  • Subramanian, RA
  • Xu, XL
  • Sheng, S
  • Jiang, Y
  • Zhou, B
  • Deodhar, A
Dates:
  • Published: June 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 29 Sep 2020 16:05
Last Modified: 29 Sep 2020 16:05
Status: Published
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export